公司概述
Medpace Holdings, Inc. operates as a specialized provider of clinical research services focused on the drug and medical device development lifecycle, serving markets across North America, Europe, Asia, South America, Africa, and Australia. The company functions within the healthcare sector, specifically the diagnostics and research industry, where it supports pharmaceutical and biotechnology clients through the entire clinical development process from Phase I to Phase IV trials. In terms of scale, the entity commands a market capitalization of $14.32B and generates annual revenue of $2.53B, supported by a workforce of 6,200 employees. These valuation and revenue figures indicate that Medpace holds a substantial position within its niche, reflecting a large-cap status with significant operational reach and a dominant footprint in the global clinical research landscape.
财务健康
The company reported a trailing twelve-month revenue of $2.53B, accompanied by a net income of $451.12M and an EBITDA of $563.06M, highlighting a distinct gap between top-line revenue and bottom-line profit that reveals a substantial cost structure involving operational expenses, taxes, and interest. This structure results in a free cash flow of $472.38M, which underscores the company's strong financial flexibility to fund ongoing operations, invest in capabilities, or manage capital allocation without immediate reliance on external financing. Profitability analysis reveals a gross margin of 71.1%, an operating margin of 21.6%, and a profit margin of 17.8%, where the high gross margin reflects the intangible nature of service delivery, while the operating and profit margins indicate the efficiency of managing overhead and delivering net earnings to shareholders. The balance sheet shows a cash position of $497.05M against total debt of $136.85M, resulting in a debt-to-equity ratio of 29.81, suggesting a leveraged yet manageable capital structure given the strong cash generation capabilities. Liquidity analysis indicates a current ratio of 0.74, which suggests that the company's current assets are lower than its current liabilities, implying a reliance on operational cash flow rather than liquid asset buffers to meet short-term obligations. Finally, return metrics show a return on equity of 70.2% and a return on assets of 16.4%, revealing exceptional management effectiveness in generating returns on shareholder capital and utilizing the asset base to produce earnings.
估值评估
The stock trades at a trailing P/E ratio of 32.78 and a forward P/E of 26.08, implying that the market expects earnings growth to accelerate significantly, as the forward multiple is notably lower than the trailing multiple. The price-to-book ratio stands at 30.99, indicating a substantial market premium over the company's book value, which is typical for high-growth service firms with significant intangible assets and proprietary networks. Alternative valuation metrics include a price-to-sales ratio of 5.66 and an EV/EBITDA of 24.64, suggesting that investors are pricing the company based on its revenue generation and earnings power relative to enterprise value rather than just historical profits. Price action over the last year ranges from a 52-week low of $250.05 to a high of $628.92, placing the current trading environment in a dynamic range that reflects recent volatility. The stock exhibits a beta of 1.39, meaning its price volatility is 39% higher than the broader market, signaling that the stock will likely experience amplified swings during periods of market stress or rally.
Growth & Income
Revenue growth for the trailing twelve months reached 32.0%, while earnings growth recorded 26.9%, indicating that earnings are growing slightly slower than revenue, which suggests that operating leverage may not have fully materialized or that costs are scaling proportionally with the rapid revenue expansion. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all net income is retained to fuel internal growth, fund research partnerships, and expand service offerings rather than distributing cash to shareholders. This reinvestment strategy aligns with the high return on equity of 70.2%, prioritizing capital appreciation over current income distribution for long-term value creation. Overall, the growth profile is defined by double-digit revenue expansion and accelerating earnings, while the income profile focuses exclusively on capital appreciation potential within a high-volatility equity class.